Analysts are intrested in these 5 stocks: ( (PLTR) ), ( (GOLD) ), ( (INTU) ), ( (NTLA) ) and ( (BYON) ). Here is a breakdown of their recent ratings and the rationale behind them.
Palantir Technologies has been upgraded to a ‘Hold’ by analyst Louie Dipalma, who sees potential in the company’s AI pipeline despite a recent 33% selloff. The stock’s valuation remains high, but positive developments, such as government contract opportunities and a rich U.S. government pipeline, offer hope. Palantir’s platforms, Foundry/AIP and Advana, are expected to benefit from a new executive order. However, the stock is expected to remain volatile, with potential downside risks due to government contract delays.
Barrick Gold has been upgraded to ‘Buy’ by analyst Daniel Major, who sees a value opportunity following the stock’s underperformance. The company is trading at a discount compared to its peers, and a potential restart of its Mali mines could act as a positive catalyst. Barrick’s medium-term copper growth and projects in high-risk jurisdictions could create significant shareholder value. The stock is valued at $22 per share, based on its EV/EBITDA ratio.
Intuit has been upgraded to ‘Buy’ by analyst Mark Murphy, who sees the company’s underperformance as an attractive entry point. Despite challenges, Intuit has continued to innovate and maintain strong business fundamentals. The QuickBooks franchise is particularly strong, with positive customer feedback and a high likelihood of recommendation. Intuit’s scale and commitment to innovation are seen as positive factors, and the stock is valued at $660 per share.
Intellia Therapeutics has initiated coverage with a ‘Buy’ rating by analyst Mitchell Kapoor, who sees potential in the company’s CRISPR/Cas9 technology. Intellia’s lead asset, NTLA-2002, offers a one-time treatment option for hereditary angioedema, with promising early data. The company’s second asset, Nex-Z, shows potential for treating transthyretin amyloidosis. Intellia is seen as undervalued, with important data updates expected in 2025.
Beyond Inc has been downgraded to ‘Hold’ by analyst Bernie Mcternan due to a significant reduction in revenue estimates. While management has improved cost efficiency, the path to profitability is now expected to be more volatile, with adjusted EBITDA-positive status pushed out to 2027. The stock’s risk-reward profile is seen as less favorable, leading to the downgrade.